Aktis Oncology

Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly.

By Frank Vinluan

BioPharma

Novartis, Bristol Myers join $72M funding for startup’s cancer radiotherapy R&D

Aktis Oncology is developing cancer radiation treatments intended to be more precise and potent compared to other radiotherapies. The startup is now out of stealth with $72 million in Series A financing.

By Frank Vinluan